WHO Emergency Use Assessment SARS-CoV-2 IVDs

PUBLIC REPORT

Product: OnSite COVID-19 Ag Rapid Test
Manufacturer: CTK Biotech, Inc.
EUL Number: EUL 0653-143-00
Outcome: Accepted

The EUL process is intended to expedite the availability of in vitro diagnostics needed in public health emergency situations and to assist interested UN procurement agencies and Member States in determining the acceptability of using specific products in the context of a Public Health Emergency of International Concern (PHEIC), based on an essential set of available quality, safety, and performance data. The EUL procedure includes the following:

- Quality Management Systems Review and Plan for Post-Market Surveillance: desk-top review of the manufacturer's Quality Management System documentation and specific manufacturing documents.
- Product Dossier Review: assessment of the documentary evidence of safety and performance.

OnSite COVID-19 Ag Rapid Test, product code R0182C, CE mark regulatory version, manufactured by CTK Biotech, Inc., 13855 Stowe Dr. Poway, CA 92064, United States of America was listed on 1 February 2022.

Intended use

According to the claim of intended use from CTK Biotech, Inc., "*OnSite COVID-19 Ag Rapid Test is a lateral flow immunoassay for the qualitative detection of SARS-CoV-2 nucleocapsid antigens in nasal swab specimens from individuals suspected of COVID-19, within the first seven days of the onset of symptoms. The test is intended for use by healthcare providers or personnel trained in rapid test procedure, as an aid in identifying SARS-CoV-2 infection.*

The OnSite COVID-19 Ag Rapid Test does not differentiate between SARS-CoV and SARS-CoV-2.

Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out other bacterial or viral infections. Positive results do not require another confirmatory testing method, but local regulatory requirement may request additional PCR testing.

Negative results from patients with symptom onset beyond seven days should be confirmed with a molecular assay. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions. Negative results should be considered in the context of a patient's recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19.

The product is intended to be used in any laboratory and non-laboratory environment that meets the requirements specified in the Instructions for Use and local regulations. For in vitro diagnostic use only.

Specimen type that was validated:

Nasal swab specimens.

Test kit contents

Component	20 tests (product code R0182C)
Individually sealed foil pouches containing: a. One cassette device b. One desiccant	20
Sealed pouch containing pre-filled extraction tubes	20
Extraction tube nozzles	20
Extraction tube rack	1
Individually sealed pouches containing a sterile swab	20
Instructions for Use	1

Items required but not provided

- Clock, watch or other timing device.
- Disposable gloves.
- Biohazard disposal container.
- A pencil or pen to label each test device.
- Positivia COVID-19 Ag Rapid Test External Control Kit (not required, sold separately).

Storage

2-30°C.

Shelf-life upon manufacture

12 months (real time stability studies are ongoing).

Warnings/limitations:

Refer to the instructions for use (IFU).

Product dossier assessment

CTK Biotech, Inc. submitted a product dossier for the OnSite COVID-19 Ag Rapid Test for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen as per the "*Instructions for Submission Requirements: In vitro diagnostics (IVDs) Detecting SARS-CoV-2 Nucleic Acid and rapid diagnostics tests detecting SARS-CoV-2 antigens (PQDx_0347)"*. The information (data and documentation) submitted in the product dossier was reviewed by WHO staff and external technical experts (assessors) appointed by WHO.

Post listing Commitments for EUL

As commitments to listing, CTK Biotech, Inc. committed to:

1. To provide a new specimen stability study report to WHO by 28 February 2022.
2. To submit a study report on traceability of all relevant materials to the WHO International Standard for SARS-CoV-2 antigen when it becomes available.
3. Estimate the LoD of the product with the WHO International Standard for SARS-CoV-2 antigen when available and to provide the report to WHO within one month of completion of the study.
4. Provide the following stability reports to WHO:
    - In-use stability by 30 June 2022.
    - Stability of unopened controls by 31 August 2022.
    - Real-time estimation of shelf-life by 30 June 2022 (1-year shelf-life), 31 December 2022 (18-month shelf-life), 30 June 2023 (24-month shelf-life) and final report by 31 July 2024.

Risk benefit assessment conclusion: acceptable.

Quality Management Systems Review

To establish the eligibility for WHO procurement, CTK Biotech, Inc. was asked to provide up-to-date information about the status of their quality management system.

Based on the review of the submitted quality management system documentation by WHO staff, it was established that sufficient information was provided by CTK Biotech, Inc. to fulfil the requirements described in the "*Instructions for Submission Requirements: In vitro diagnostics (IVDs) Detecting SARS-CoV-2 Nucleic Acid and rapid diagnostics tests detecting SARS-CoV-2 antigens (PQDx_347)*".

Quality management documentation assessment conclusion: acceptable.

Plan for Post-Market Surveillance

Post-market surveillance, including monitoring all customer feedback, detecting, and acting on adverse events, product problems, non-conforming goods and processes is critical component of minimizing potential harm of an IVD listed for emergency use.

The following post-EUL activities are required to maintain the EUL listing status:
1. Notification to WHO of any planned changes to a EUL product, in accordance with "*WHO procedure for changes to a WHO prequalified in vitro diagnostic" (document number PQDx_121*); and
2. Post-market surveillance activities, in accordance with "*Guidance for post-market surveillance and market surveillance of medical devices, including in vitro diagnostics"* (ISBN 978-92-4-001531-9).

CTK Biotech, Inc. is also required to submit all categories of complaints in a summarized form. There are certain categories of complaints and changes to the product that must be notified immediately to WHO, as per the above-mentioned documents.

The manufacturer has committed to ensure that post-emergency use listing safety, quality and performance monitoring activities are in place which are in accordance with WHO guidance "*Guidance for post-market surveillance and market surveillance of medical devices, including in vitro diagnostics*" (ISBN 978-92-4-001531-9).[1]

Scope and duration of procurement eligibility

OnSite COVID-19 Ag Rapid Test, product code R0182C, manufactured by CTK Biotech, Inc. is considered to be eligible for WHO procurement for 12 months from the day of listing. The assay may be used for the detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen. This listing does not infer that the product meets WHO prequalification requirements and does not mean that the product is listed as WHO prequalified.

As part of the on-going requirements for listing as eligible for WHO procurement, CTK Biotech, Inc. must engage in post-market surveillance activities to ensure that the product continues to meet safety, quality, and performance requirements. CTK Biotech, Inc. is required to notify WHO of any complaints, including adverse events related to the use of the product within 7 days and any changes to the product.

WHO reserves the right to rescind eligibility for WHO procurement, if additional information on the safety, quality, performance during post-market surveillance activities, and if new data becomes available to WHO that changes the risk benefit balance.

[1] Available on the web page https://www.who.int/publications/i/item/guidance-for-post-market-surveillance-and-market-surveillance-of-medical-devices-including-in-vitro-diagnostics

Labelling

1.0 Labels

2.0 Instructions for Use (IFU)

1.0 Product labels

1.1 Kit box design label

Lateral flow immunoassay for the qualitative detection of SARS-CoV-2 nucleocapsid antigens in nasopharyngeal (NP) or nasal swab specimens from individuals suspected of COVID-19, within the first seven days of the onset of symptoms. It is intended to be used by healthcare providers as an aid in identifying SARS-CoV-2 infection.

Σ 20

CE

Contains	20	Individually packed cassette devices
	20	Sealed pre-filled extraction tubes
	20	Extraction tube nozzles
	20	Sealed pouches containing a sterile swab
	1	Sample extraction tube rack
	1	Instructions for Use

REF	R0182C		yyyy-mm-dd
LOT	xxxxxxx		yyyy-mm-dd

CTK Biotech, Inc.
13855 Stowe Drive
Poway, CA 92064, USA

EC REP MDSS GmbH
Schiffgraben 41
30175 Hannover, Germany

Barcode for RTR Use Only

10108900

PL-R0182C-2-FS Rev D

C=38 M=55 Y=0 K=0

C=91 M=92 Y=1 K=0

C=0 M=51 Y=100 K=0

C = 76 M = 0 Y= 52 K=0

PM-R0182C Rev.A
OnSite COVID-19 Ag RDT kit box design file Revision A
Effective date: 09/29/2020
Dimension: 205 X 122 X 70 mm



PM-R0182C Rev A

1.2 Component labels

CTK BIOTECH SIMPLIFYING DIAGNOSTICS	**COVID-19 Ag Rapid Test** **Labeling - R0182C, 20T/kit**

Item	Component	Label Template
1.	Pouch Material code RM0257 Document code: PC-R0180C Rev. A Size:120 x 65mm	 
2.	Cassette Material code RM-0182C Doc code RM-R0182C Rev. B Size 20 x 72 mm	
3.	Pre-filled, foil sealed extraction tube (Controlled by BGB) Material code RM3387	
4.	Nozzle	 

5.	Swab (From swab supplier) Size 150mm (length)	 See swab label below on separate page
6.	Kit box Material code PM-R0182C Doc code PM-R0182C Rev. A Size 205 x 122 x 70 mm	
7.	Sample extraction buffer PL-SB-R0182-FS Rev D Size: 55 x 20 mm	 

8.	Kit box label Doc code PL-R0182C-2-FS Rev D Size 146 x 95 mm	*Lateral flow immunoassay for the qualitative detection of SARS-CoV-2 nucleocapsid antigens in nasopharyngeal (NP) or nasal swab specimens from individuals suspected of COVID-19, within the first seven days of the onset of symptoms. It is intended to be used by healthcare providers as an aid in identifying SARS-CoV-2 infection.* Σ 20 CE **Contains** 20 Individually packed cassette devices 20 Sealed pre-filled extraction tubes 20 Extraction tube nozzles 20 Sealed pouches containing a sterile swab 1 Sample extraction tube rack 1 Instructions for Use REF R0182C LOT xxxxxxx yyyy-mm-dd yyyy-mm-dd CTK Biotech, Inc. 13855 Stowe Drive Poway, CA 92064, USA EC REP MDSS GmbH Schiffgraben 41 30175 Hannover, Germany PL-R0182C-2-FS Rev D
9.	Paper tube rack	

Swab Label





Noble Biosciences, Inc.
25, Ganeunggol 1-gil, Bongdam-eup, Hwaseong-si,
Gyeonggi-do, Korea
TEL. +82-31-291-0044, FAX. +82-31-291-0046

EC REP
S.B PHARMA GMBH
Max-Planck Str.39a D-50858, Koin, Germany
TEL. +49 (0) 2234 988 1521

OnSite COVID-19 Ag Rapid Test

IVD

2

Ag

CE

REF

LOT

2023-12-03

2021-12-06

CTK BIOTECH

PASSED

YF-06.

CE

COVID-19 AG RAPID TEST

CTK

COVID-19 Ag Rapid Test

COVID-19 Ag Rapid Test

0182C CE

tions for Use

2.0 Instructions for use[2]

[2] English version of the IFU was assessed by WHO. It is the responsibility of the manufacturer to ensure correct translation into other languages.

OnSite® COVID-19 Ag Rapid Test

REF R0182C CE

10108900

Barcode for RTR Use Only

Instructions for Use

INTENDED USE

The *OnSite* COVID-19 Ag Rapid Test is a lateral flow immunoassay for the qualitative detection of SARS-CoV-2 nucleocapsid antigens in nasal swab specimens from individuals suspected of COVID-19, within the first seven days of the onset of symptoms. The test is intended for use by healthcare providers or personnel trained in rapid test procedure, as an aid in identifying SARS-CoV-2 infection.

The *OnSite* COVID-19 Ag Rapid Test does not differentiate between SARS-CoV and SARS-CoV-2.

Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out other bacterial or viral infections. Positive results do not require another confirmatory testing method, but local regulatory requirement may request additional PCR testing.

Negative results from patients with symptom onset beyond seven days should be confirmed with a molecular assay. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions. Negative results should be considered in the context of a patient's recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19.

The product is intended to be used in any laboratory and non-laboratory environment that meets the requirements specified in the Instructions for Use and local regulations. For *in vitro* diagnostic use only.

SUMMARY AND EXPLANATION OF THE TEST

SARS-CoV-2 belongs to the broad family of coronaviruses which are capable of causing illnesses ranging from the common cold to more severe diseases[1]. SARS-CoV-2 infections cause COVID-19 disease resulting in a wide range of clinical symptoms, ranging from asymptomatic to fever, tiredness and dry cough, and possibly leading to severe sickness and even death. Most patients recover without special treatment. According to recent data, approximately 15-20% of infected individuals become seriously ill and develop difficulty breathing[2]. The elderly and those with underlying medical problems, such as high blood pressure, heart problems or diabetes are more likely to develop serious illness[2].

Human-to-human transmission of the virus has been confirmed and occurs primarily via respiratory droplets from coughs and sneezes within a range of about six feet (1.8 m)[3]. Viral RNA has also been found in stool samples from patients. It is possible that the virus can be infectious even during the incubation period, but this has not yet been proven[4].

The current laboratory method for detecting COVID-19 is PCR. However, this method requires sophisticated equipment and highly trained laboratory technicians. The *OnSite* COVID-19 Ag Rapid Test is an easy-to-use and cost-efficient assay that can be performed at point-of-care settings.

The *OnSite* COVID-19 Ag Rapid Test detects the presence of antigens from the SARS-CoV-2 virus within the first seven days of the onset of symptoms. Test results should be interpreted at 15 minutes. Results should not be interpreted after 20 minutes. Minimally skilled personnel can perform the test, without the use of cumbersome laboratory equipment.

TEST PRINCIPLE

The *OnSite* COVID-19 Ag Rapid Test is a lateral flow chromatographic immunoassay. The test cassette consists of: 1) a colored conjugate pad containing anti-SARS-CoV-2 antibodies conjugated with colloidal gold (antibody conjugates) and 2) a nitrocellulose membrane strip containing a test line (Ag line) and a control line (C line). The test line is pre-coated with anti-SARS-CoV-2 antibodies and the C line is pre-coated with control antibodies. The specimen is collected with a nasal swab and the SARS-CoV-2 antigen is extracted from the swab with extraction buffer. When applied to the sample well, the extracted specimen migrates across the test strip by capillary action. SARS-CoV-2 antigen, if present in the extract, binds to the antibody conjugates and the immunocomplex is then captured on the membrane by the pre-coated anti-SARS-CoV-2 antibody, forming a colored Ag line that indicates a COVID-19 positive test result.

The test contains an internal control (C line), which should exhibit a colored line regardless of color development on the Ag line. If the C line does not develop, the test result is invalid and the specimen must be retested with a new device.

REAGENTS AND MATERIALS PROVIDED

1. 20 Individually sealed foil pouches containing:
   a. One cassette device
   b. One desiccant
2. 20 Sealed pouch containing pre-filled extraction tubes
3. 20 Extraction tube nozzles
4. 1 Extraction tube rack
5. 20 Individually sealed pouches containing a sterile swab
6. 1 Instructions for Use

MATERIALS REQUIRED BUT NOT PROVIDED

1. Clock, watch or other timing device
2. Disposable gloves, biohazard disposal container
3. A pencil or pen to label each test device and the Positivia COVID-19 Ag Rapid Test External Control Kit (not required, sold separately)

WARNINGS AND PRECAUTIONS

For *In Vitro* Diagnostic Use

1. Read these Instructions for Use completely before performing the test. Failure to follow these instructions could lead to inaccurate test results.
2. Do not open the sealed pouch unless ready to conduct the assay.
3. Do not use expired devices.
4. Bring all reagents to room temperature (15-30°C) before use.
5. Do not use the components in any other type of test kit as a substitute for the components in this kit.
6. Wash hands thoroughly before and after testing. We recommend wearing disposable gloves while handling kit reagents and clinical specimens.
7. Do not smoke, drink or eat in areas where specimens or kit reagents are being handled.
8. Dispose of all specimens and materials used to perform the test as biohazardous waste.
9. Read the test results 15 minutes after specimen is applied to the sample well. Consider any results read after 20 minutes invalid and repeat the test.
10. Do not perform the test in a room with strong air flow, i.e. an electric fan or strong air-conditioning.

REAGENT PREPARATION AND STORAGE INSTRUCTIONS

All reagents are ready to use as supplied. Store unused devices unopened at 2-30°C. If stored at 2-8°C, ensure that the device is brought to room temperature before opening. The cassette device is stable until the expiration date printed on the sealed pouch. Do not freeze the kit or expose the kit to temperatures above 30°C.

ASSAY PROCEDURE

1. Before running the assay, ensure the test area is sanitized. Open the kit and ensure all materials described in "Reagents and Materials Provided" are included and the kit is not expired. Obtain a timing device (clock, watch or timer) and read the Quick Reference Guide and these Instructions for Use. Consider any materials of human origin as potentially infectious, and handle them with standard biosafety procedures
2. Wash or sanitize hands thoroughly and put on gloves and additional personal protective equipment (PPE) following local healtcare and authority guidelines.
3. Fold/assemble the sample extraction tube rack.
4. Remove one pre-filled extraction tube from the sealed pouch and close the pouch with the unused tubes. Hold the pre-filled extraction tube upright and, before opening it, tap the bottom of the tube on a clean, flat surface to ensure that liquid on the seal is moved down into the tube.
5. Carefully remove the foil seal from the extraction tube, and place the open tube in the sample extraction tube rack provided with the kit.
6. Remove mucus from the patient's nose.
7. Open the swab package.

   Note: Do not touch the swab's absorbent tip, so be sure to open the package on the opposite end.
8. Holding the patient's head in a vertical position and looking slightly downwards, carefully insert the entire absorbent tip of the swab in one nostril and rotate at least 5 times. **Be sure that the absorbent tip of the swab scrapes against the nasal wall. Stop when you feel resistance (no more than 2 cm into the nose).**
9. Remove swab from nostril and, using the same swab, repeat step 8 in the other nostril.
10. Withdraw the swab from the nasal cavity. Insert the absorbent tip of the swab into the extraction buffer tube and swirl the swab at least 5 times.
11. Squeeze the tube against the submerged swab at least 5 ti
12. Lift the swab out of the liquid and squeeze the tube against the fabric tip to remove excess fluid from the swab. Remove the swab, place it back in its original wrapping and dispose into a biohazard disposal container.
13. Place the nozzle onto the extraction tube and ensure it is attached firmly.
14. Remove the cassette device from the sealed pouch just prior to testing. Lay the device on a clean, flat surface and label with specimen ID/name.
15. Invert the sample extraction tube and **slowly add 3 drops of the extracted specimen into the sample well of the cassette device by gently squeezing the sample tube.**
16. Set the timing device for 15 minutes.
17. Read the results after 15 minutes.

    Note: The result might be visible after a shorter time, however, it should only be interpreted between 15-20 minutes after dispensing the sample material onto the cassette device.







Collect all used items (swab, cassette, sample extraction tube, foil seal and nozzle, and used gloves) and discard as biohazardous waste following local laws governing the disposal of devices.

INTERPRETATION OF ASSAY RESULT

NEGATIVE RESULT: If only the C line develops, the test did not detect SARS-CoV-2 virus (antigen) in the specimen. The result is negative or non-reactive.

POSITIVE RESULT: If both the C line and Ag line develop, SARS-CoV or SARS-CoV-2 virus (antigen) is detected in the specimen. The result is positive or reactive. Some specimens might produce a faint band, but every visible test line band indicates a positive result independently of the band intensity.



INVALID: If no C line develops, the assay is invalid regardless of color development on the Ag line. Repeat the assay with a new device.



QUALITY CONTROL

1. **Internal Control**: This test contains a built-in control feature, the C line. If the C line does not develop after sample application, the result is invalid. Review the entire procedure and repeat the test with a new device.
2. **External Control:** External controls for the OnSite COVID-19 Ag Rapid Test are available and sold separately (Positivia COVID-19 Ag Rapid Test External Control Kit catalog number C0182C). Good Laboratory Practice recommends using external controls, positive and negative, to ensure the proper performance of the assay, particularly under the following circumstances:

   a. A new operator uses the kit, prior to performing the testing of specimens.
   b. A new lot of test kits is use

c. A new shipment of test kits is used
d. The temperature during storage of the kits falls outside of 2-30°C.
e. The temperature of the test area falls outside of 15-30°C.
f. To verify a higher than expected frequency of positive or negative results.
g. To investigate the cause of repeated invalid results.

PERFORMANCE CHARACTERISTICS

1. Clinical Performance

The clinical performance of the *OnSite* COVID-19 Ag Rapid Test was evaluated at five clinical sites (Colombia, Brazil, India, Bangladesh and Slovakia), in nasal swabs pecimens collected from subjects suspected of COVID-19. Two swabs were collected from each subject, one nasal swab for testing by the *OnSite* COVID-19 Ag Rapid Test and one NP swab for testing by commercially available real-time Polymerase Chain Reaction (RT-PCR) assay for the detection of SARS-CoV-2, used as the reference method for this study. The combined performance of the *OnSite* COVID-19 Ag Rapid Test in these studies is shown on the table below:

RT-PCR Test (Reference)	*OnSite* COVID-19 Ag Rapid Test Result		
	Positive	Negative	Total
Positive	155	15	170
Negative	2	523	525
Total	157	538	695

Relative Sensitivity: 91.2% (95% CI: 85.9-95.0%); Relative Specificity: 99.6% (95% CI: 98.6-100%); Overall Agreement: 97.6% (95% CI: 96.1-98.6%)

Stratification of the positive specimens post onset of symptoms.

Days since Symptom Onset	OnSite COVID-19 Ag Rapid Test Positive	PCR Positive	Agreement	95% CI
≤1	5	5	100%	47.8%-100%
≤2	31	33	93.9%	80.0%-99.3%
≤3	75	84	89.3%	80.6%-95.0%
≤4	108	121	89.3%	82.3%-94.2%
≤5	133	148	89.9%	83.8%-94.2%
≤6	144	159	90.6%	84.9%-94.6%
≤7	151	166	91.0%	85.5%-94.9%
Total	155*	170	91.2%	85.9%-95.0%

*There were 4 positive specimens collected at 8-9 days post onset of symptoms

The positive agreement of the *OnSite* COVID-19 Ag Rapid Test with the reference RT-PCR tests in these studies is presented in the table below relative to the average RT-PCR target Ct values, representative of the SARS-CoV-2 viral load in the samples:

RT-PCR Results		*OnSite* COVID-19 Ag Rapid Test Results		
Average target Ct value	N positives	N positives	Positive agreement	95% CI
<24	108	105	97.2%	92.0% - 99.4%
<27	119	116	97.5%	92.8% - 99.5%
<30	125	121	96.8%	92.0% - 99.1%
<33	132	125	94.7%	89.4% - 97.8%
All	170	155	91.2%	85.9% - 95.0%

2. Analytical Performance

2.1 Analytical Sensitivity (Limit of Detection, LoD)

The LoD of the *OnSite* COVID-19 Ag Rapid Test was determined by evaluating a serial dilution of Gamma-Irradiated SARS-CoV-2 virus lysate (BEI Resources, NR-52287). Multiple negative nasal swab specimens were eluted in extraction buffer and were combined and mixed thoroughly to create clinical negative matrix pools for each matrix, to be used as the diluent. Inactivated SARS-CoV-2 virus lysate was diluted in each of these matrices to generate virus dilutions for testing. Each sample was spiked with 50 µL of each virus dilution, extracted with extraction buffer and tested according to the product IFU. The assay LoD was determined for nasal swab specimens as the lowest concentration that was detected ≥ 95% of the time in the respective specimen matrix.

The LoD of the *OnSite* COVID-19 Ag Rapid Test in nasal swab matrices was determined to be 466.7 $TCID_{50}$/mL. The *OnSite* COVID-19 Ag Rapid Test can detect the U.K. South Africa and Brazil variants at similar levels as the original SARS-CoV-2 strain.

2.2 Analytical Specificity (Cross-Reactivity and Microbial Interference)

The analytical specificity of the *OnSite* COVID-19 Ag Rapid Test was evaluated by testing commensal and pathogenic microorganisms that may be present in the nasal cavity. Each of the organisms was tested in triplicate in the presence of 2-3X LoD recombinant SARS-CoV-2 NP antigen. No cross-reactivity (except SARS-coronavirus) or interference were seen with the following microorganisms when tested at the concentration presented in the table below:

Potential Cross-Reactant	Concentration	Cross-Reactivity (Yes/No)	Microbial Interference (Yes/No)
SARS-coronavirus NP antigen	25 µg/mL	Yes (3/3 positive)	No (3/3 positive)
MERS-coronavirus NP antigen	25 µg/mL	No (3/3 negative)	No (3/3 positive)
Human coronavirus HKU1 NP antigen	66 µg/mL	No (3/3 negative)	No (3/3 positive)
Human coronavirus 229E	1.77×10^5 $TCID_{50}$/mL	No (3/3 negative)	No (3/3 positive)
Human coronavirus OC43	0.53×10^5 $TCID_{50}$/mL	No (3/3 negative)	No (3/3 positive)
Human coronavirus NL63	0.51×10^5 $TCID_{50}$/mL	No (3/3 negative)	No (3/3 positive)
Adenovirus	7×10^8 NIU/mL	No (3/3 negative)	No (3/3 positive)
Human Metapneumovirus (hMPV)	0.76×10^4 $TCID_{50}$/mL	No (3/3 negative)	No (3/3 positive)
Parainfluenza virus 1	5.01×10^4 $TCID_{50}$/mL	No (3/3 negative)	No (3/3 positive)
Parainfluenza virus 2	1.6×10^5 $TCID_{50}$/mL	No (3/3 negative)	No (3/3 positive)
Parainfluenza virus 3	1.6×10^6 $TCID_{50}$/mL	No (3/3 negative)	No (3/3 positive)
Parainfluenza virus 4	1.15×10^5 $TCID_{50}$/mL	No (3/3 negative)	No (3/3 positive)
Influenza A NP antigen	180 µg/mL	No (3/3 negative)	No (3/3 positive)
Influenza B NP antigen	200 µg/mL	No (3/3 negative)	No (3/3 positive)
Enterovirus	2.8×10^5 $TCID_{50}$/mL	No (3/3 negative)	No (3/3 positive)
Respiratory syncytial virus	2.8×10^4 $TCID_{50}$/mL	No (3/3 negative)	No (3/3 positive)
Rhinovirus	2.2×10^5 PFU/mL	No (3/3 negative)	No (3/3 positive)
Haemophilus influenzae	5.2×10^5 CFU/mL	No (3/3 negative)	No (3/3 positive)
Streptococcus pneumoniae	$>2\times10^3$ CFU/mL	No (3/3 negative)	No (3/3 positive)
Streptococcus pyogenes	3.6×10^5 CFU/mL	No (3/3 negative)	No (3/3 positive)
Candida albicans	4.5×10^6 $TCID_{50}$/mL	No (3/3 negative)	No (3/3 positive)
Pooled human nasal wash – *representative of normal respiratory microbial flora*	N/A	No (3/3 negative)	No (3/3 positive)
Bordetella pertussis	3.9×10^7 CFU/mL	No (3/3 negative)	No (3/3 positive)
Mycoplasma pneumoniae	4.4×10^5 CFU/mL	No (3/3 negative)	No (3/3 positive)
Chlamydophila pneumoniae	1.4×10^7 IFU/mL	No (3/3 negative)	No (3/3 positive)
Legionella pneumophila	7.8×10^5 CFU/mL	No (3/3 negative)	No (3/3 positive)
Mycobacterium tuberculosis	$>2\times10^3$ CFU/mL	No (3/3 negative)	No (3/3 positive)
Pneumocystis jirovecii (PJP)	3.45×10^6 CFU/mL	No (3/3 negative)	No (3/3 positive)

3. Interfering Substances

The following potentially interfering substances, naturally present in respiratory specimens or that may be artificially introduced into the nasal cavity, were evaluated with the *OnSite* COVID-19 Ag Rapid Test at the concentrations listed in the following table and were found not to affect test performance for detection of both positive and negative specimens:

Interfering Substance	Concentration	Interference (Yes/No)	Interfering Substance	Concentration	Interference (Yes/No)
Mucin	0.5%	No (6/6 correct)	Ribavirin	1 mg/mL	No (6/6 correct)
Whole Blood	4%	No (6/6 correct)	Peramivir	1 mg/ml	No (6/6 correct)
Phenylephrine	15% v/v	No (6/6 correct)	Tobramycin	4 µg/mL	No (6/6 correct)
Fluconazole	5% w/v	No (6/6 correct)	Diphenhydramine	0.08 mg/dL	No (6/6 correct)
Budesonide	5% w/v	No (6/6 correct)	Dextromethorphan	1.56 µg/dL	No (6/6 correct)
Nasal Gel	2% v/v	No (6/6 correct)	Acetaminophen	199 uM	No (6/6 correct)
Menthol	1.5 mg/mL	No (6/6 correct)	Acetylsalicylic Acid	3 mg/dL	No (6/6 correct)
Benzocaine	1.5 mg/mL	No (6/6 correct)	Mupirocin	10 mg/mL	No (6/6 correct)
Lopinavir	5 mg/mL	No (6/6 correct)	HAMA	4 ng/mL	No (6/6 correct)
Zanamivir	5 mg/mL	No (6/6 correct)	Biotin	100 ug/mL	No (6/6 correct)
Oseltamivir	5 mg/mL	No (6/6 correct)			

4. Hook Effect

No high dose hook effect was observed when tested with up to a concentration of 3×10^8 pg/mL of recombinant SARS-CoV-2 NP antigen with the *OnSite* COVID-19 Ag Rapid Test.

LIMITATIONS OF TEST

1. The Assay Procedure and the Interpretation of Assay Result must be followed closely when testing for the presence of SARS-CoV-2 antigen in the swab specimen from individual subjects. For optimal test performance, proper sample collection is critical. Failure to follow the procedure may lead to inaccurate results.
2. It is intended for use only by healthcare professionals or personnel trained in rapid test procedure. For *in vitro* diagnostic use only.
3. The *OnSite* COVID-19 Ag Rapid Test is limited to the qualitative detection of SARS-CoV-2 antigen. The intensity of the test line does not have linear correlation with virus titer in the specimen.
4. Sensitivity can differ with various strains of SARS-CoV-2 due to differences of antigen expression. Specimens might contain a new or non-identified strain of SARS-CoV-2 that expresses varying amounts of antigen.
5. A negative or non-reactive result for an individual subject indicates absence of detectable of SARS-CoV-2 antigen. However, a negative or non-reactive result does not preclude the possibility of SARS-CoV-2 virus infection.
6. A negative or non-reactive result can occur if the quantity of the SARS-CoV-2 virus (antigen) present in the specimen is below the detection limit of the assay, or if the virus detected was not present in the swab specimen sampled, or the viruses have undergone minor amino acid mutation in the epitope recognized by the antibody utilized in the test.
7. The *OnSite* COVID-19 Ag Rapid Test detects both viable and non-viable SARS-CoV and SARS-CoV-2 antigens. Test performance depends on antigen loaded in the sample. A positive test does not rule out the possibility that other pathogens may be present.
8. Performance of the test has not been established for monitoring antiviral treatment of SARS-CoV-2 infection.

REFERENCES

1. Naming the coronavirus disease (COVID-19) and the virus that causes it. (n.d.). Retrieved from https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it.
2. "Frequently Asked Questions - General Assembly of the United Nations." United Nations, www.un.org/pga/75/coronavirus/faqs/.
3. World Health Organization. (2020). Advice on the use of masks in the community, during home care, and in health care settings in the context of COVID-19: interim guidance, 19 March 2020 (No. WHO/2019-nCoV/IPC_Masks/2020.2). World Health Organization.
4. Healthcare Professionals: Frequently Asked Questions and Answers. (2020, March 22). Retrieved from https://www.cdc.gov/coronavirus/2019-ncov/hcp/faq.html.

Index of Symbols

	Consult instructions for use	IVD	For *in vitro* diagnostic use only		Use by
REF	Catalog #	LOT	Lot Number	N	Tests per kit
2°C 30°C	Store between 2-30°C	EC REP	Authorized Representative		Do not reuse
	Manufacturer		Date of manufacture		

CTK Biotech, Inc.
13855 Stowe Drive,
Poway, CA 92064, USA
Tel: 858-457-8698
Fax: 858-535-1739
E-mail: info@ctkbiotech.com

EC REP **MDSS GmbH**
Schiffgraben 41
30175 Hannover, Germany

PI-R0182C-FS-NW-EUL Rev. E
Date released: 2022-01-31
English version

For Export Only, Not For Re-sale in the USA.